SC
EW icon

Skylands Capital’s Edwards Lifesciences EW Stock Holding History

Skylands Capital’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-600
Closed -$9K – 250
2014
Q2 		$9K Sell
600
-37,200
-98% -$504K ﹤0.01% 247
2014
Q1 		$467K Sell
37,800
-13,800
-27% -$159K 0.05% 184
2013
Q4 		$566K Buy
+51,600
New +$582K 0.06% 164

Other funds holding EW

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Skylands Capital's EW Position: Q3 2014 in Review

Skylands Capital sold out of Edwards Lifesciences (EW) in Q3 2014, closing a stake of 600 shares — an estimated $9K sold.

Skylands Capital first reported a position in EW in Q4 2013 and held it in 3 quarters. The position peaked at $566K in Q4 2013. 496 funds tracked by Wall St. Rank hold EW as of Q3 2014.

  • Skylands Capital reported no remaining Edwards Lifesciences position as of Q3 2014 after selling out during the quarter.
  • Skylands Capital sold 600 Edwards Lifesciences shares in Q3 2014, an estimated $9K.
  • Skylands Capital first reported a position in Edwards Lifesciences in Q4 2013 and held it in 3 quarters.
  • Skylands Capital's Edwards Lifesciences position peaked at $566K in Q4 2013.
  • 496 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2014.

Based on Skylands Capital's 13F filing for Q3 2014, filed 23 Oct 2014.